Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
76 of 180 long COVID-associated genes also linked to ME
This campaign is to raise awareness about the crucial role helmet usage plays in saving lives
Growing patent filings and tier-2 innovators reflect expanding national research base
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Subscribe To Our Newsletter & Stay Updated
